Clear cell carcinoma of the ovary: Characterization of its CD44 isoform repertoire

Gynecologic Oncology

Volumn 79, Issue 2, 2000, Pages 187-195

  Sancho Torres, Inés ^a   Mesonero, Clara ^b   Miller Watelet, Jean Luc ^a   Gibbon, Darlene ^a,b   Rodríguez Rodríguez, Lorna ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; MESSENGER RNA;

ARTICLE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033767778     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5938     Document Type: Article

References (33)

1. Molecular inhibition of cancer invasion and metastasis
2. Molecular insights into cancer invasion: Strategies for prevention and intervention
3. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression
4. CD44v3, 8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells
5. The CD44 protein family
6. CD44 is a metastasis suppressor gene for the prostatic cancer located on human chromosome 11p13
7. Current status of CD44 variant isoforms as cancer diagnostic markers
8. Clinical characteristics of the clear cell carcinoma of the ovary
9. Biologic prognostic factors in ovarian cancer: A review
10. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer
11. CD44 expression patterns in breast and colon tumors
12. CD44 variant expression is a common feature of ovarian cancer: Lack of association with standard prognostic factors
13. Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas
14. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relationship to prognosis
15. The prognosis value of CD44 isoform expression in endometrial cancer
16. CD44v6 expression in human colorectal carcinoma
17. CD44 splice variant expression in clear cell carcinoma of the ovary
18. Progressive loss of CD44 gene expression in invasive bladder cancer
19. Expression and modulation of CD44 variant isoforms in humans
20. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: Comparison with cystadenomas and overt carcinomas
21. CD44 is not involved in the metastatic spread of ovarian cancer in vivo
22. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer
23. Binding of ovarian cancer cells to peritoneal, mesothelium in vitro is partly mediated by CD44H
24. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: A novel role for CD44 in the process of peritoneal implantation
25. Functional heterogeneity of CD44 molecules in the ovarian cancer cell lines
26. Immunohistochemical detection of CD44 splice variant expression in premalignant lesions of the cervix and benign cervical epithelium
27. Regulated expression of exon v6 containing isoforms of CD44 in man: Downregulation during malignant transformation of tumors of squamocellular origin
28. Prognostic value of CD44 splice variant expression in ovarian cancer
29. Expression of CD44 alternative splicing variants in primary and lymph node metastatic lesions of gynecological cancer
30. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer
31. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer
32. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells